ASX:MSBBiotechs
Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?
Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with Duchenne muscular dystrophy, using time-to-stand at nine months as the primary approval endpoint.
This move extends the use of the first FDA-approved mesenchymal stromal cell therapy beyond steroid‑refractory pediatric graft-versus-host disease and leverages a partnership with Parent Project...